A REAL-WORLD ANALYSIS OF FIRST LINE NIVOLUMAB COMBINED WITH DOXORUBICIN, VINBLASTINE, AND DACARBAZINE (N-AVD) IN CLASSICAL HODGKIN LYMPHOMA (CHL) – A SINGLE CENTER COHORT STUDY
EHA Library, Liat Shargian,
4210133
QUALITY OF LIFE OUTCOMES WITH TAFASITAMAB + LENALIDOMIDE AND RITUXIMAB FOR RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (R/R FL): RESULTS FROM THE PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED INMIND STUDY
EHA Library, Paolo Strati,
4210158
INTERIM AND END-OF-TREATMENT (EOT) PET/CT ASSESSMENT AFTER NIVOLUMAB, DOXORUBICIN, VINBLASTINE, AND DACARBAZINE (N-AVD) IN ADVANCED-STAGE CLASSICAL HODGKIN LYMPHOMA (CHL): A SINGLE-CENTER EXPERIENCE
EHA Library, Alexia Piperidou,
4210129
NAVIGATING THE POST–COVALENT BRUTON TYROSINE KINASE INHIBITOR LANDSCAPE IN MANTLE CELL LYMPHOMA: REAL-WORLD INSIGHTS ON TREATMENT PATTERNS, DISCONTINUATION, AND HEALTHCARE RESOURCE UTILIZATION
EHA Library, Toby A. Eyre,
4210167